Director/PDMR Shareholding

RNS Number : 9789X
Nuformix PLC
10 January 2022
 

10 January 2022

Nuformix plc

 

("Nuformix" or the "the Company")

   

Director/PDMR Shareholding

 

Nuformix plc  (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that today the Company received notice that Dr Alastair Riddell purchased 400,000 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 1.175 pence per share on 10 January 2022.

 

- Ends -

 

Nuformix plc

via Walbrook

Dr Alastair Riddell, Executive Chairman






 

Allenby Capital Limited

 

+44 (0) 20 3328 5656

Nick Athanas / George Payne (Corporate Finance)


Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)




 

Walbrook PR

 

nuformix@walbrookpr.com  or +44 (0)20 7933 8780

Anna Dunphy / Phillip Marriage

Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082







  Enquiries:

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Dr Alastair Riddell

2

 

Reason for the notification

 

a)

 

Position/status

 

PDMR - Executive Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Nuformix plc

b)

 

LEI

 

2138003XG3H3I2J3BJ24

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of nominal value 0.1 pence each

 

 

GB00BYW79Y38

b)

 

Nature of the transaction

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

1.175p

 

400,000

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

- Total

 

 

400,000

 

1.175p

 

£4,700.00

e)

 

Date of the transaction

 

10 January 2022

f)

 

Place of the transaction

 

London Stock Exchange, Main Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPUUPGUPPGQU

Companies

Nuformix (NFX)
UK 100